Home > Keywords > Thématique > Partenariat

Partenariat

Articles

  • Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases
    30 June, by Emmanuelle BETTENDORF

    Vect-Horus is pleased to announce that we have entered into a research evaluation and exclusive license option agreement with Servier, an independent international pharmaceutical group, to develop targeted oligonucleotide therapeutics for the treatment of central nervous system (CNS) diseases.
    Under the agreement, we will leverage our proprietary VECTrans® technology platform to facilitate the transport of Servier’s oligonucleotide therapeutics across biological barriers to the brain, (…)

  • Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
    3 February, by Emmanuelle BETTENDORF

    We are delighted to announce we have entered into a Material Transfer and Evaluation Agreement with OliX Pharmaceuticals, a leading developer of RNAi therapeutics, to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.
    “We are extremely pleased to partner with OliX. This collaboration underscores Vect-Horus’ leadership in BBB technology and its commitment to advancing oligonucleotide therapeutics in CNS diseases through strategic partnerships with (…)

  • Vect-Horus and RadioMedix announce the signing of a LOI to co-develop a Vect-Horus’ radio-theranostic agent for Glioblastoma
    6 March 2019, by Jonathan NOWAK

    Marseille, France- Houston - March 5, 2019 - Vect-Horus and RadioMedix announced today the signing of a Letter of Intent (LOI) to establish an agreement for the co-development of a Vect-Horus theranostic agent for the diagnostic and radiotherapy of Glioblastoma Multiforme (GBM) of the brain.
    This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and (…)

  • RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC
    19 September 2025, by Emmanuelle BETTENDORF

    Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).
    “The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.
    “We are looking forward (…)

  • Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
    11 July 2025, by Emmanuelle BETTENDORF

    We are proud and excited to announce a new strategic research collaboration with Secarna Pharmaceuticals!
    The partnership will focus on developing RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) to address diseases of the central nervous system (CNS), combining our delivery technology platform, VECTrans®, with Secarna’s proprietary OligoCreator® oligonucleotide discovery platform.
    The combination of these two technologies will expand Secarna’s targeted (…)

  • Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics
    1 November 2023, by Emmanuelle BETTENDORF

    Vect-Horus, a privately held biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has entered into a global license agreement with Novo Nordisk A/S. This agreement provides Novo Nordisk with worldwide, exclusive license to use Vect-Horus platform technology ”VECTrans”; for delivery of cargos directed against specified targets . Novo Nordisk has an option to add additional targets to the (…)

  • Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
    28 January 2019, by Jonathan NOWAK

    The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

  • Vect-Horus announces agreement with Johnson&Johnson Innovation
    18 January 2019, by Jonathan NOWAK

    Vect-Horus announced today the signing of a research collaboration agreement with Janssen Pharmaceuticals, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • Relocation of the company to support its development
    1 October 2019, by Elodie DORMES

    Relocation of Vect-Horus in medical faculty of the La Timone campus to maintain strong collaborative working environment with its historical partners and support its development.

  • Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel Khrestchatisky, Director of the UMR7259 laboratory (CNRS and Aix-Marseille University) and involves the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA. This project received (…)